Cassava Sciences Appoints Freda Nassif as Chief Commercial Officer
Cassava Sciences (NASDAQ: SAVA) has appointed Freda Nassif as Chief Commercial Officer, effective immediately. Nassif, who brings extensive experience in developing commercial strategies for FDA-approved drugs, will report to President and CEO Rick Barry. This appointment comes as Cassava prepares for its first Phase 3 topline data readout for simufilam, their novel Alzheimer's disease treatment, expected before the end of 2024. The company views this strategic hire as important for potential product launch preparations, pending positive trial results and FDA approval.
Cassava Sciences (NASDAQ: SAVA) ha nominato Freda Nassif come Chief Commercial Officer, con effetto immediato. Nassif, che porta una vasta esperienza nello sviluppo di strategie commerciali per farmaci approvati dalla FDA, riporter脿 al Presidente e CEO Rick Barry. Questa nomina arriva mentre Cassava si prepara per il suo primo rilascio di dati top-line della Fase 3 per simufilam, il loro nuovo trattamento per la malattia di Alzheimer, atteso prima della fine del 2024. L'azienda considera questa assunzione strategica importante per le preparazioni al lancio del prodotto, in attesa di risultati positivi degli studi clinici e dell'approvazione della FDA.
Cassava Sciences (NASDAQ: SAVA) ha nombrado a Freda Nassif como Directora Comercial, con efecto inmediato. Nassif, quien aporta una amplia experiencia en el desarrollo de estrategias comerciales para medicamentos aprobados por la FDA, reportar谩 al Presidente y CEO Rick Barry. Este nombramiento llega mientras Cassava se prepara para su primer resultado de datos top-line de la Fase 3 para simufilam, su nuevo tratamiento para la enfermedad de Alzheimer, que se espera antes de finales de 2024. La empresa considera que esta contrataci贸n estrat茅gica es importante para los preparativos del lanzamiento del producto, a la espera de resultados positivos de los ensayos y la aprobaci贸n de la FDA.
旃挫偓氚� 靷澊鞏胳姢 (NASDAQ: SAVA)電� 頂勲爤雼� 雮橃嫓頂�毳� 斓滉碃 靸侅梾 毂呾瀯鞛愲 歃夓嫓 鞛勲獏頄堨姷雼堧嫟. 雮橃嫓頂勲姅 FDA 鞀轨澑 鞎诫鞚� 靸侅梾 鞝勲灥 臧滊皽鞐� 雽�頃� 甏戨矓鞙勴暅 瓴巾棙鞚� 臧�歆�瓿� 鞛堨溂氅�, 靷灔 瓴� CEO鞚� 毽� 氚半Μ鞐愱矊 氤搓碃頃� 瓴冹瀰雼堧嫟. 鞚� 鞛勲獏鞚� 旃挫偓氚旉皜 鞎岇笭頃橃澊毹� 氤� 旃橂鞝滌澑 鞁滊頃勲瀸鞚� 觳� 氩堨Ц 3靸� 欤检殧 雿办澊韯� 瓿店皽毳� 2024雲� 毵� 鞝勳溂搿� 鞓堨儊頃橂┐靹� 鞚措（鞏挫鞀惦媹雼�. 須岇偓電� 旮嶌爼鞝侅澑 鞁滍棙 瓴瓣臣鞕� FDA 鞀轨澑鞚� 旮半嫟毽┌ 鞝滍拡 於滌嫓 欷�牍勳棎 鞛堨柎 鞚� 鞝勲灥鞝� 毂勳毄鞚� 欷戩殧頃橂嫟瓿� 氤搓碃 鞛堨姷雼堧嫟.
Cassava Sciences (NASDAQ: SAVA) a nomm茅 Freda Nassif au poste de Directrice Commerciale, avec effet imm茅diat. Nassif, qui apporte une vaste exp茅rience dans le d茅veloppement de strat茅gies commerciales pour des m茅dicaments approuv茅s par la FDA, fera rapport au Pr茅sident et CEO Rick Barry. Cette nomination intervient alors que Cassava se pr茅pare pour sa premi猫re lecture des donn茅es top-line de la Phase 3 pour simufilam, leur nouveau traitement de la maladie d'Alzheimer, pr茅vue avant la fin de 2024. L'entreprise consid猫re cette embauche strat茅gique comme importante pour les pr茅paratifs de lancement du produit, en attendant des r茅sultats d'essai positifs et l'approbation de la FDA.
Cassava Sciences (NASDAQ: SAVA) hat Freda Nassif mit sofortiger Wirkung zur Chief Commercial Officer ernannt. Nassif bringt umfangreiche Erfahrung in der Entwicklung von Handelsstrategien f眉r von der FDA zugelassene Medikamente mit und wird an Pr盲sident und CEO Rick Barry berichten. Diese Ernennung erfolgt, w盲hrend Cassava sich auf die erste Topline-Datenver枚ffentlichung der Phase 3 f眉r Simufilam, ihre neuartige Alzheimer-Therapie, vorbereitet, die noch vor Ende 2024 erwartet wird. Das Unternehmen betrachtet diese strategische Einstellung als wichtig f眉r die Vorbereitungen zum Produktlaunch, abh盲ngig von positiven Testergebnissen und der FDA-Zulassung.
- Strategic timing of CCO appointment ahead of Phase 3 trial results
- Preparation for potential commercial launch indicates confidence in trial outcome
- Addition of experienced commercial leadership for FDA-approved drug strategies
- Success depends on pending Phase 3 trial results
- Commercial launch contingent on FDA approval
Ms. Nassif brings an extensive track record of successfully developing commercial strategies for multiple FDA-approved drugs
Appointment initiates Cassava鈥檚 commercial readiness strategy as the Company prepares for
first Phase 3 topline data readout before year end 2024
AUSTIN, Texas, Nov. 18, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA), a clinical-stage biotechnology company focused on developing a novel treatment for Alzheimer鈥檚 disease, today announced the appointment of Freda Nassif as Chief Commercial Officer, effective today. As a member of the Company鈥檚 executive leadership team, Ms. Nassif will report to Richard 鈥淩ick鈥� Barry, President and Chief Executive of Cassava.
鈥淚 am thrilled to expand Cassava鈥檚 leadership team and welcome Freda Nassif as Chief Commercial Officer. She joins our company at a critical time, ahead of the release of topline results from RETHINK-ALZ, our first Phase 3 trial for simufilam, expected by the end of 2024, and potential product launch,鈥� said Rick Barry, President and Chief Executive Officer. 鈥淔reda brings to Cassava a proven track record of successfully developing and implementing effective commercial strategies for innovative medicines. Pending positive simufilam Phase 3 results and FDA approval, we believe Freda鈥檚 extensive expertise will be invaluable to the development of a robust commercial plan. She will play a key role in helping to realize our ambitious goal of reimagining the treatment possibilities for Alzheimer鈥檚 disease.鈥�
Freda Nassif, Chief Commercial Officer of Cassava commented, 鈥淚 am honored to have the opportunity to lead the commercial organization for a novel therapy at a time in which there are unprecedented challenges for people living with Alzheimer鈥檚 Disease. Developing innovative commercial strategies has been the focus of my career and I look forward to bringing my experience to a company like Cassava that is committed to transforming the treatment paradigm."
About Freda Nassif, Chief Commercial Officer
Ms. Nassif is an accomplished biopharmaceutical executive with 25 years of experience, including leading commercial teams to blockbuster status for Pfizer, Inc., Novartis Oncology, Merck & Company, Inc. and Bristol Myers Squibb. In addition, Ms. Nassif has partnered with Fortune 100 life science, pharma, and biotech companies where she has been a major contributor to the commercial growth strategies of high-value, established and emerging brands including Zepbound庐, Entyvio庐, Tzield庐, Epclusa庐, and Takhzyro庐.
Ms. Nassif has received numerous career awards including Pfizer鈥檚 鈥淰ice President Cabinet Award鈥�. Ms. Nassif earned her MBA and Bachelor of Science from Drexel University.
About Cassava Sciences, Inc.
Cassava Sciences is a clinical-stage biotechnology company based in Austin, Texas. Our mission is to detect and treat neurodegenerative diseases, such as Alzheimer鈥檚 disease.
Simufilam is an investigational oral, small molecule drug candidate currently being evaluated in two Phase 3 clinical trials for the potential treatment of Alzheimer's disease. Simufilam targets a specific site on filamin A, a scaffolding protein that is critical to certain receptor interactions in the brain.聽Cassava Sciences believes that simufilam interrupts amyloid-尾42 binding to receptors in the brain and may affect the Alzheimer's disease process. Cassava Sciences owns exclusive, worldwide rights to its investigational product candidates and related technologies, without royalty obligations to any third party.
For more information, please visit:
Zepbound庐 is a registered trademark of Eli Lilly and Company
Entyvio庐 is a registered trademark of Takeda Pharmaceuticals U.S.A.
Tzield庐 is a registered trademark of Sanofi S.A.
Epclusa庐 is a trademark of Gilead Sciences, Inc.
Takhzyro庐 is a registered trademark of Takeda Pharmaceuticals U.S.A.
For More Information Contact:
Investors
Sandya von der Weid
Media
Sitrick And Company
Company
Eric Schoen, Chief Financial Officer
(512) 501-2450
Cautionary Note Regarding Forward-Looking Statements:
This news release contains forward-looking statements that include but are not limited to statements regarding: the completion and future results of our Phase 3 clinical studies of simufilam in patients with Alzheimer's disease; the development of our commercial strategy; the timing of anticipated milestones; and the potential for simufilam to be approved as a treatment for Alzheimer鈥檚 disease. These statements may be identified by words such as 鈥渁nticipate鈥�, 鈥渂efore,鈥� 鈥渂elieve鈥�, 鈥渃ould鈥�, 鈥渆xpect鈥�, 鈥渇orecast鈥�, 鈥渋ntend鈥�, 鈥渕ay鈥�, 鈥減ending,鈥� 鈥減lan鈥�, 鈥減ossible鈥�, 鈥減otential鈥�, 鈥減repares for,鈥� 鈥渨ill鈥�, and other words and terms of similar meaning.
Such statements are based on our current expectations and projections about future events. Such statements speak only as of the date of this news release and are subject to a number of risks, uncertainties and assumptions, including, but not limited to, those risks relating to the ability to conduct or complete clinical studies on expected timelines; the ability to demonstrate the specificity, safety, efficacy or potential health benefits of simufilam; our current expectations regarding timing of clinical data for our Phase 3 studies; and other risks inherent in drug discovery and development or specific to Cassava Sciences, Inc., as described in the section entitled 鈥淩isk Factors鈥� in our Annual Report on Form 10-K for the year ended December 31, 2023 and Quarterly Report on Form 10-Q for the period ended September 30, 2024, and future reports to be filed with the SEC. The foregoing sets forth many, but not all, of the factors that could cause actual results to differ from expectations in any forward-looking statement. In light of these risks, uncertainties and assumptions, the forward-looking statements and events discussed in this news release are inherently uncertain and may not occur, and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. Accordingly, you should not rely upon forward-looking statements as predictions of future events. Except as required by law, we disclaim any intention or responsibility for updating or revising any forward-looking statements. For further information regarding these and other risks related to our business, investors should consult our filings with the SEC, which are available on the SEC's website at .
All of our pharmaceutical assets under development are investigational product candidates. These have not been approved for use in any medical indication by any regulatory authority in any jurisdiction and their safety, efficacy or other desirable attributes, if any, have not been established in any patient population. Consequently, none of our product candidates is approved or available for sale anywhere in the world.
FAQ
When will Cassava Sciences (SAVA) release Phase 3 topline results for simufilam?
Who is the new Chief Commercial Officer at Cassava Sciences (SAVA)?
What is the purpose of SAVA's new CCO appointment?
